Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06684509 | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 46 | Assiut UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06671717 | Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | not yet recruiting | N/A | 25 | Peking University People's HospitalOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | not yet recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06667583 | 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients | not yet recruiting | — | 40 | Assiut UniversityOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06669143 | Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06658938 | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06659770 | A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma | not yet recruiting | — | 200 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06652139 | Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | not yet recruiting | Phase 2 | 82 | Ruijin HospitalOTHER | 0 | Oct 22, 2024 | clinicaltrials |
| NCT06652152 | Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma(DEL Biomarker) | not yet recruiting | — | 400 | Ruijin HospitalOTHER | 0 | Oct 22, 2024 | clinicaltrials |
| NCT06651203 | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study(KISS01) | not yet recruiting | — | 460 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 21, 2024 | clinicaltrials |
| NCT06646211 | High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06549335 | Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) | not yet recruiting | Phase 2 | 66 | Ruijin HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06594211 | Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma | not yet recruiting | N/A | 18 | RenJi HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594432 | Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06573099 | A Real-World Study on Extranodal Lymphoma | not yet recruiting | — | 5,000 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573138 | Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | not yet recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06559644 | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | not yet recruiting | Early Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | not yet recruiting | Phase 2 | 528 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 24, 2024 | clinicaltrials |
| NCT06500507 | A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 90 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06482931 | Bleeding in Multiple Myeloma(BiMM) | not yet recruiting | — | 160 | University Medical Center GroningenOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT06472479 | LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 66 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06465446 | A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | not yet recruiting | Phase 3 | 202 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06450821 | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications | not yet recruiting | N/A | 60 | University of LeedsOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | not yet recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06416267 | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)(MBL RiskConseq) | not yet recruiting | — | 1,500 | University of HaifaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05982275 | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant(CARTemis-1) | not yet recruiting | Phase 1 / Phase 2 | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05718986 | Familial B-cell Lymphoproliferative Disorders(Familial_LPD) | not yet recruiting | — | 1,000 | University of HaifaOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | not yet recruiting | — | 260 | Peking University People's HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06333509 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | not yet recruiting | Phase 1 / Phase 2 | 166 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06318884 | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 76 | Sinocelltech Ltd.INDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | not yet recruiting | Phase 2 | 10 | Dalian Medical UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06314828 | A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 | 30 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06286228 | Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease(Haplo) | not yet recruiting | — | 43 | Siriraj HospitalOTHER | 0 | Mar 1, 2024 | clinicaltrials |
| NCT06116929 | Hodgkin's Disease and Chemotherapy Before 40 Years(FunC-AHOD) | not yet recruiting | N/A | 63 | Lille Catholic UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT05627115 | Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma(RATiFY) | not yet recruiting | Phase 2 | 80 | University College, LondonOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | not yet recruiting | Early Phase 1 | 72 | Salarius Pharmaceuticals, LLCINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2024source: clinicaltrials